Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study

Direct oral anticoagulants (DOACs) have been promoted in patients with nonvalvular atrial fibrillation (nv‐AF) as a more convenient alternative to vitamin K antagonists. We estimated 1‐year dabigatran and rivaroxaban adherence rates in nv‐AF patients and assessed associations between baseline patient characteristics and nonadherence.

[1]  A. Pariente,et al.  Identifying atrial fibrillation in outpatients initiating oral anticoagulants based on medico‐administrative data: results from the French national healthcare databases , 2017, Pharmacoepidemiology and drug safety.

[2]  Ulrich Schotten,et al.  2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. , 2017, Revista espanola de cardiologia.

[3]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[4]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[5]  P. Hjemdahl,et al.  Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation , 2016, European Journal of Clinical Pharmacology.

[6]  M. Steffen.  Universalism, Responsiveness, Sustainability--Regulating the French Health Care System. , 2016, The New England journal of medicine.

[7]  J. Beyer-Westendorf,et al.  Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[8]  G. Caleb Alexander,et al.  Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation , 2016, Journal of the American Heart Association.

[9]  J. Segal,et al.  Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation , 2015, Journal of managed care & specialty pharmacy.

[10]  C. McHorney,et al.  Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure , 2015, Current medical research and opinion.

[11]  M. Lapeyre-Mestre,et al.  French health insurance databases: What interest for medical research? , 2015, La Revue de medecine interne.

[12]  N. Hagiwara,et al.  Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: A single-center observational study , 2015, Journal of arrhythmia.

[13]  M. Turakhia,et al.  Site-level variation in and practices associated with dabigatran adherence. , 2015, JAMA.

[14]  H. Heidbuchel,et al.  Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[15]  F. Skjøth,et al.  Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study , 2015, Journal of thrombosis and haemostasis : JTH.

[16]  S. Kimmel,et al.  Factors affecting time to maintenance dose in patients initiating warfarin , 2015, Pharmacoepidemiology and drug safety.

[17]  T. Nabeshima,et al.  Pharmacist-managed clinics for patient education and counseling in Japan: current status and future perspectives , 2015, Journal of Pharmaceutical Health Care and Sciences.

[18]  Richard White,et al.  A Retrospective Descriptive Analysis of Patient Adherence to Dabigatran at a Large Academic Medical Center , 2014, Journal of managed care & specialty pharmacy.

[19]  Paul L. Hess,et al.  Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. , 2014, American heart journal.

[20]  G. Grunwald,et al.  Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. , 2014, American heart journal.

[21]  Yilong Wang,et al.  Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the China national stroke registry. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[22]  J. Dean,et al.  Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice , 2014, Internal medicine journal.

[23]  C. Murray,et al.  Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study , 2014, Circulation.

[24]  S. Yusuf,et al.  The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). , 2014, Journal of the American College of Cardiology.

[25]  L. Køber,et al.  Antiplatelet Therapy for Stable Coronary Artery Disease in Atrial Fibrillation Patients Taking an Oral Anticoagulant: A Nationwide Cohort Study , 2014, Circulation.

[26]  A. Harada,et al.  Adherence, persistence, and switching patterns of dabigatran etexilate. , 2013, The American journal of managed care.

[27]  M. Zálešák,et al.  Higher Persistence in Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran Versus Warfarin , 2013, Circulation. Cardiovascular quality and outcomes.

[28]  J. Cairns,et al.  Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease. , 2013, The Canadian journal of cardiology.

[29]  D. Fitzmaurice,et al.  Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review. , 2013, Health technology assessment.

[30]  J. Eikelboom,et al.  Adherence to anticoagulant treatment with dabigatran in a real‐world setting , 2013, Journal of thrombosis and haemostasis : JTH.

[31]  Chris M Kozma,et al.  Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis , 2013, Patient preference and adherence.

[32]  L. Wallentin,et al.  New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis , 2013, European heart journal.

[33]  P. Wells,et al.  Non‐adherence to new oral anticoagulants: a reason for concern during long‐term anticoagulation? , 2013, Journal of thrombosis and haemostasis : JTH.

[34]  C. Bennett,et al.  Will Newer Anticoagulants Improve Therapy Persistence?: Comment on “Persistence With Therapy Among Patients Treated With Warfarin for Atrial Fibrillation” , 2012 .

[35]  Maochao Xu,et al.  Comparison of pharmacy-based measures of medication adherence , 2012, BMC Health Services Research.

[36]  Jeffrey K Aronson,et al.  A new taxonomy for describing and defining adherence to medications. , 2012, British journal of clinical pharmacology.

[37]  Gordon H Guyatt,et al.  Executive Summary Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2012 .

[38]  J. Broderick,et al.  Withdrawal of Antithrombotic Agents and Its Impact on Ischemic Stroke Occurrence , 2011, Stroke.

[39]  D. Singer,et al.  Warfarin Discontinuation After Starting Warfarin for Atrial Fibrillation , 2010, Circulation. Cardiovascular quality and outcomes.

[40]  A. Localio,et al.  Can we predict daily adherence to warfarin?: Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. , 2010, Chest.

[41]  M. Fang,et al.  Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism , 2010, Patient preference and adherence.

[42]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[43]  Bradley C Martin,et al.  Good and poor adherence: optimal cut-point for adherence measures using administrative claims data , 2009, Current medical research and opinion.

[44]  Grégoire Rey,et al.  Ecological association between a deprivation index and mortality in France over the period 1997 – 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death , 2009, BMC public health.

[45]  K. Chan,et al.  Methods for evaluation of medication adherence and persistence using automated databases , 2006, Pharmacoepidemiology and drug safety.

[46]  Marsha A Raebel,et al.  Measurement of Adherence in Pharmacy Administrative Databases: A Proposal for Standard Definitions and Preferred Measures , 2006, The Annals of pharmacotherapy.

[47]  M. Cheang,et al.  Validity of a Prescription Claims Database to Estimate Medication Adherence in Older Persons , 2006, Medical care.

[48]  S. De Geest,et al.  Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[49]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[50]  A V Prochazka,et al.  The assessment of refill compliance using pharmacy records: methods, validity, and applications. , 1997, Journal of clinical epidemiology.